Non-small cell lung cancer
Conditions
Interventions
Cross-line group:None. Continue Endostar antiangiogenic therapy after the first progression
Non-cross-line group:None. Endostar antiangiogenic therapy is no longer used after the first progression
Sponsors
The first affiliated hostipal of nanchang university
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.IIIB-IV non-small cell lung cancer (NSCLC) patients with histopathologically confirmed TNM stage; 2.Between the ages of 18 and 75, with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-2; 3.The presence of one or more measurable double-diameter tumor foci was assessed according to the Solid Tumor Response Evaluation Criteria (RECIST, 1.1) ; 4.Endostar combined with platinum-containing double-drug chemotherapy was initially accepted as first-line treatment, during which programmed cell death protein-1 (PD-1) inhibitors were allowed, and the efficacy was evaluated as disease progression (PD); 5. Have not received any prior anti-tumor therapy and have an expected survival time of more than 3 months
Exclusion criteria
Exclusion criteria: 1.Combined with primary tumors of other sites; 2.Genetic testing indicated the presence of a positive gene mutation; 3.Pregnant or lactating women; 4.Incomplete medical records or failed follow-up; 5.Poor compliance or abandonment of treatment for personal reasons; 6.The treatment course was less than 2 cycles, and the efficacy could not be evaluated;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Disease control rate;Adverse reactions; | — |
Countries
China
Contacts
Public ContactZhihui Lu
The first affiliated hostipal of nanchang university
Outcome results
None listed